The Technical Analyst
EyeGate Pharmaceuticals [EYEG]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
EyeGate Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.14% $34.71
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 64.18 mill |
| EPS: | -1.768 |
| P/E: | -19.63 |
| Earnings Date: | Nov 08, 2021 |
| SharesOutstanding: | 1.849 mill |
| Avg Daily Volume: | 0.0003 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/20 | 3/20 | 4/20 | 1/21 | 2/21 | 3/21 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -19.63 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -3.34x |
| Company: PE -19.63 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 34.59 - 34.84 ( +/- 0.36%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-11-02 | From Stephen | Sell | 250 | Common Stock |
| 2021-11-02 | Mann Brenda | Sell | 62 | Common Stock |
| 2021-10-04 | Mann Brenda | Sell | 62 | Common Stock |
| 2021-10-04 | From Stephen | Sell | 249 | Common Stock |
| 2021-09-02 | From Stephen | Sell | 253 | Common Stock |
| INSIDER POWER |
|---|
| 0.00 |
| Last 98 transactions |
| Buy: 1 959 813 | Sell: 207 057 |
Forecast:
11:33 - $34.75
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $34.71 (0.14% ) |
| Volume | 0.0058 mill |
| Avg. Vol. | 0.0003 mill |
| % of Avg. Vol | 1 889.25 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EYEG
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
EYEG
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Waltham, Massachusetts and currently employs 11 full-time employees. The firm is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The firm's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
Last 10 Buy Signals
Latest Press Releases
2021-09-09 16:15:00 - Press Release
Eyegate To Present At The H.c. Wainwright 23rd Annual Global Investment Conference
Waltham, mass., sept. 09, 2021 (globe newswire) -- eyegate pharmaceuticals, inc. (nasdaq: eyeg), (“eyegate” or the “company”), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that eyegate's president and chief executive officer, brian m. strem, ph.d., will provide a corporate update and participate in one-on-one investor meetings at the h.c. wainwright 23rd annual global investment conference to be held september 13-15, 2021.
2021-09-08 06:55:00 - Press Release
Eyegate Pharma Completes Target Enrollment In Phase 2 Proof-of-concept Study To Evaluate Pp-001 For The Treatment Of Ocular Surface Inflammation
-proof-of-concept study conducted in austria; study designed to build upon positive phase 1 safety data in healthy volunteers-
2021-08-12 16:15:00 - Press Release
Eyegate Pharma Reports Second Quarter 2021 Financial Results And Provides Business Update
Waltham, mass., aug. 12, 2021 (globe newswire) -- eyegate pharmaceuticals, inc. (nasdaq: eyeg), (“eyegate” or the “company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, today reported its financial results for the quarter ended june 30, 2021 and provided an update on recent corporate and operational activities.
2021-08-10 06:55:00 - Press Release
Eyegate Announces $10.75 Million Registered Direct Offering Priced At-the-market Under Nasdaq Rules
Waltham, mass., aug. 10, 2021 (globe newswire) -- eyegate pharmaceuticals, inc. (nasdaq: eyeg) (“eyegate” or the “company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale, in a registered direct offering priced at-the-marked under nasdaq rules, of 4,668,844 shares of its common stock at a purchase price of $2.3025 per share for gross proceeds of approximately $10.75 million, before deducting placement agent's fees and other offering expenses...
2021-07-26 16:15:00 - Press Release
Eyegate Pharmaceuticals Announces Appointment Of Brian M. Strem, Ph.d.
-eyegate signs non-binding letter of intent to acquire bayon therapeutics, a private ophthalmic pharmaceutical company developing a novel, vision restoring small molecule platform- -eyegate signs non-binding letter of intent to acquire bayon therapeutics, a private ophthalmic pharmaceutical company developing a novel, vision restoring small molecule platform-
Latest News
2021-10-01 05:19:54 - Pulse2
EYEG Stock Price: Why It Substantially Increased
The stock price of Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) increased 22.95% in the previous trading session. This is why it happened.
2021-09-29 10:20:06 - InvestorPlace
7 Best Penny Stocks to Buy on the Nasdaq for October
Penny stocks have a place in every portfolio when adjusted for risk. These 7 have the added safety of a Nasdaq listing.
2021-09-24 13:55:54 - PennyStocks
Best Penny Stocks to Buy Right Now? 3 to Watch in October
Investing in penny stocks in 2021? Check these three out for next months watchlist The post Best Penny Stocks to Buy Right Now?
2021-09-15 11:04:57 - PennyStocks
Penny Stocks For Your Biotech Watch List In September 2021
Penny stocks that may be worth watching right now. The post Penny Stocks For Your Biotech Watch List In September 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-09-14 12:21:38 - PennyStocks
4 Penny Stocks To Buy According To Analysts & Price Targets Up To 507%
Biotech Penny Stocks Surge As Sector Reverses Course The post 4 Penny Stocks To Buy According To Analysts & Price Targets Up To 507% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-09-09 16:15:00 - GlobeNewsWire
EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that EyeGate's President and Chief Executive Officer, Brian M. Strem, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021.
2021-09-08 06:55:00 - GlobeNewsWire
EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation
-Proof-of-concept study conducted in Austria; Study designed to build upon positive Phase 1 safety data in healthy volunteers-
2021-08-20 13:00:00 - PennyStocks
Top Penny Stocks You Need to Know About Right Now
Are these top penny stocks on your small-caps watchlist The post Top Penny Stocks You Need to Know About Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-08-12 16:15:00 - GlobeNewsWire
EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update
WALTHAM, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, today reported its financial results for the quarter ended June 30, 2021 and provided an update on recent corporate and operational activities.
2021-08-10 07:36:06 - Pulse2
EYEG Stock Price Falls Over 14% Pre-Market: Why It Happened
The stock price of Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) fell by over 14% pre-market. This is why it happened.